Malignant Pleural Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major malignant pleural mesothelioma markets reached a value of US$ 318.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 632.6 Million by 2034, exhibiting a growth rate (CAGR) of 6.45% during 2024-2034.
The malignant pleural mesothelioma market has been comprehensively analyzed in IMARC's new report titled "Malignant Pleural Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Malignant pleural mesothelioma refers to a type of cancer that develops in the pleura, a tissue covering the lungs and chest wall. Depending on the types of cells in the mesothelium where the malignancy begins, this disease is categorized into epithelioid, sarcomatoid, and biphasic mesothelioma. The primary symptoms of the ailment include ongoing shortness of breath and chest pain. Individuals suffering from malignant pleural mesothelioma may also experience persistent cough, hoarseness, difficulty swallowing, lower back pain, swollen face and arms, unexplained weight loss, night sweats, fatigue, fever, etc. The diagnosis of this disease is based on a physical exam, blood tests, a review of the patient's medical history, and an assessment of risk factors. The healthcare provider may perform various diagnostic procedures, including chest X-rays, magnetic resonance imaging, positron emission tomography scans, etc., to visualize the location of tumors and the extent of the disease. Additionally, a bronchoscopy or thoracoscopy is required to confirm a diagnosis.
The increasing cases of exposure to asbestos fibers, which cause inflammation and scarring within the pleura, are primarily driving the malignant pleural mesothelioma market. Apart from this, the rising incidences of several associated risk factors, including specific genetic mutations, smoking, exposure to high levels of radiation, etc., are also bolstering the market growth. Furthermore, the widespread adoption of immunotherapy as a treatment option for malignant pleural mesothelioma, since it modifies and improves the defense system's ability to recognize and destroy cancer cells, is creating a positive outlook for the market. Besides this, the escalating utilization of thoracentesis, a minimally invasive technique for removing excess fluid from the pleural space and relieving various symptoms, including shortness of breath and chest pain, is also augmenting the market growth. Moreover, several key players are making extensive investments in R&D activities to launch novel radiation therapy techniques that can reduce the risk of damage to healthy lung tissue and improve lung function. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene and photodynamic therapies, which can fight the disease more effectively with fewer side effects, thereby improving the quality of life for patients, is expected to drive the malignant pleural mesothelioma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the malignant pleural mesothelioma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for malignant pleural mesothelioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the malignant pleural mesothelioma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the malignant pleural mesothelioma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the malignant pleural mesothelioma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current malignant pleural mesothelioma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the malignant pleural mesothelioma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the malignant pleural mesothelioma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the malignant pleural mesothelioma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of malignant pleural mesothelioma across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant pleural mesothelioma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant pleural mesothelioma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with malignant pleural mesothelioma across the seven major markets?
What is the size of the malignant pleural mesothelioma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of malignant pleural mesothelioma?
What will be the growth rate of patients across the seven major markets?
Malignant Pleural Mesothelioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for malignant pleural mesothelioma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the malignant pleural mesothelioma market?
What are the key regulatory events related to the malignant pleural mesothelioma market?
What is the structure of clinical trial landscape by status related to the malignant pleural mesothelioma market?
What is the structure of clinical trial landscape by phase related to the malignant pleural mesothelioma market?
What is the structure of clinical trial landscape by route of administration related to the malignant pleural mesothelioma market?
The malignant pleural mesothelioma market has been comprehensively analyzed in IMARC's new report titled "Malignant Pleural Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Malignant pleural mesothelioma refers to a type of cancer that develops in the pleura, a tissue covering the lungs and chest wall. Depending on the types of cells in the mesothelium where the malignancy begins, this disease is categorized into epithelioid, sarcomatoid, and biphasic mesothelioma. The primary symptoms of the ailment include ongoing shortness of breath and chest pain. Individuals suffering from malignant pleural mesothelioma may also experience persistent cough, hoarseness, difficulty swallowing, lower back pain, swollen face and arms, unexplained weight loss, night sweats, fatigue, fever, etc. The diagnosis of this disease is based on a physical exam, blood tests, a review of the patient's medical history, and an assessment of risk factors. The healthcare provider may perform various diagnostic procedures, including chest X-rays, magnetic resonance imaging, positron emission tomography scans, etc., to visualize the location of tumors and the extent of the disease. Additionally, a bronchoscopy or thoracoscopy is required to confirm a diagnosis.
The increasing cases of exposure to asbestos fibers, which cause inflammation and scarring within the pleura, are primarily driving the malignant pleural mesothelioma market. Apart from this, the rising incidences of several associated risk factors, including specific genetic mutations, smoking, exposure to high levels of radiation, etc., are also bolstering the market growth. Furthermore, the widespread adoption of immunotherapy as a treatment option for malignant pleural mesothelioma, since it modifies and improves the defense system's ability to recognize and destroy cancer cells, is creating a positive outlook for the market. Besides this, the escalating utilization of thoracentesis, a minimally invasive technique for removing excess fluid from the pleural space and relieving various symptoms, including shortness of breath and chest pain, is also augmenting the market growth. Moreover, several key players are making extensive investments in R&D activities to launch novel radiation therapy techniques that can reduce the risk of damage to healthy lung tissue and improve lung function. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene and photodynamic therapies, which can fight the disease more effectively with fewer side effects, thereby improving the quality of life for patients, is expected to drive the malignant pleural mesothelioma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the malignant pleural mesothelioma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for malignant pleural mesothelioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the malignant pleural mesothelioma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the malignant pleural mesothelioma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the malignant pleural mesothelioma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current malignant pleural mesothelioma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the malignant pleural mesothelioma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the malignant pleural mesothelioma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the malignant pleural mesothelioma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of malignant pleural mesothelioma across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant pleural mesothelioma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of malignant pleural mesothelioma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with malignant pleural mesothelioma across the seven major markets?
What is the size of the malignant pleural mesothelioma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of malignant pleural mesothelioma?
What will be the growth rate of patients across the seven major markets?
Malignant Pleural Mesothelioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for malignant pleural mesothelioma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the malignant pleural mesothelioma market?
What are the key regulatory events related to the malignant pleural mesothelioma market?
What is the structure of clinical trial landscape by status related to the malignant pleural mesothelioma market?
What is the structure of clinical trial landscape by phase related to the malignant pleural mesothelioma market?
What is the structure of clinical trial landscape by route of administration related to the malignant pleural mesothelioma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MALIGNANT PLEURAL MESOTHELIOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MALIGNANT PLEURAL MESOTHELIOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MALIGNANT PLEURAL MESOTHELIOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MALIGNANT PLEURAL MESOTHELIOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MALIGNANT PLEURAL MESOTHELIOMA - UNMET NEEDS
10 MALIGNANT PLEURAL MESOTHELIOMA - KEY ENDPOINTS OF TREATMENT
11 MALIGNANT PLEURAL MESOTHELIOMA - MARKETED PRODUCTS
11.1 List of Malignant Pleural Mesothelioma Marketed Drugs Across the Top 7 Markets
11.1.1 Opdivo (Nivolumab) - Bristol-Myers Squibb/Ono Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Yervoy (Ipilimumab) - Bristol Myers Squibb
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MALIGNANT PLEURAL MESOTHELIOMA - PIPELINE DRUGS
12.1 List of Malignant Pleural Mesothelioma Pipeline Drugs Across the Top 7 Markets
12.1.1 MTG201 - Momotaro-Gene
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CBP501 - CanBas
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Lurbinectedin - PharmaMar
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MALIGNANT PLEURAL MESOTHELIOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MALIGNANT PLEURAL MESOTHELIOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MALIGNANT PLEURAL MESOTHELIOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Malignant Pleural Mesothelioma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Malignant Pleural Mesothelioma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Malignant Pleural Mesothelioma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Malignant Pleural Mesothelioma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Malignant Pleural Mesothelioma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Malignant Pleural Mesothelioma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Malignant Pleural Mesothelioma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Malignant Pleural Mesothelioma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
16 MALIGNANT PLEURAL MESOTHELIOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MALIGNANT PLEURAL MESOTHELIOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MALIGNANT PLEURAL MESOTHELIOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MALIGNANT PLEURAL MESOTHELIOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MALIGNANT PLEURAL MESOTHELIOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MALIGNANT PLEURAL MESOTHELIOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MALIGNANT PLEURAL MESOTHELIOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MALIGNANT PLEURAL MESOTHELIOMA - UNMET NEEDS
10 MALIGNANT PLEURAL MESOTHELIOMA - KEY ENDPOINTS OF TREATMENT
11 MALIGNANT PLEURAL MESOTHELIOMA - MARKETED PRODUCTS
11.1 List of Malignant Pleural Mesothelioma Marketed Drugs Across the Top 7 Markets
11.1.1 Opdivo (Nivolumab) - Bristol-Myers Squibb/Ono Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Yervoy (Ipilimumab) - Bristol Myers Squibb
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MALIGNANT PLEURAL MESOTHELIOMA - PIPELINE DRUGS
12.1 List of Malignant Pleural Mesothelioma Pipeline Drugs Across the Top 7 Markets
12.1.1 MTG201 - Momotaro-Gene
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CBP501 - CanBas
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Lurbinectedin - PharmaMar
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MALIGNANT PLEURAL MESOTHELIOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MALIGNANT PLEURAL MESOTHELIOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MALIGNANT PLEURAL MESOTHELIOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Malignant Pleural Mesothelioma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Malignant Pleural Mesothelioma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Malignant Pleural Mesothelioma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Malignant Pleural Mesothelioma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Malignant Pleural Mesothelioma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Malignant Pleural Mesothelioma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Malignant Pleural Mesothelioma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Malignant Pleural Mesothelioma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Malignant Pleural Mesothelioma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Malignant Pleural Mesothelioma - Access and Reimbursement Overview
16 MALIGNANT PLEURAL MESOTHELIOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MALIGNANT PLEURAL MESOTHELIOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MALIGNANT PLEURAL MESOTHELIOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
